Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose IV serelaxin safety study in chronic heart failure
NL-OMON40917Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing Serelaxin with Placebo (2 arms). Primary endpoint: Anti-serelaxin antibody development. Started Nov 2014; status: active, not recruiting.
02
Drugs
serelaxin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON40917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40917.